On Tuesday, Morgan Stanley (NYSE:MS) resumed coverage of BeiGene , Ltd. (NASDAQ:BGNE) shares with an Overweight rating and set a new price target of $300.00. The $21.86 billion market cap company has shown impressive momentum, with a 40.69% price return over the past six months.
The firm's analysis highlighted the growing market share of BeiGene's drug Brukinsa, due to its superior safety and efficacy as a second-generation BTK inhibitor. They also pointed out that the potential of Brukinsa in the European market is not fully recognized in current revenue projections. According to InvestingPro data, the company's current Fair Value suggests it remains undervalued despite recent gains.
The coverage noted emerging data that suggests Eli Lilly (NYSE:LLY)'s third-generation BTK inhibitor, Jaypirca, may remain a second-line treatment compared to Brukinsa, even though first-line data is expected in the first quarter of 2025.
The analyst also emphasized the significance of BGB-16683, a BTK degrader within BeiGene's pipeline, as a strategic asset that could mitigate potential market disruptions in the future. BeiGene's strong market position is reflected in its impressive 50.22% revenue growth and 83.67% gross profit margin in the last twelve months.
Furthermore, the report mentioned Sonrotoclax, a BCL2 inhibitor, as a potentially best-in-class therapy. The combination of Sonrotoclax with Brukinsa could present a compelling treatment option, according to Morgan Stanley's analysis. This combination is part of BeiGene's strategic moves to strengthen its position in the market.
The Overweight rating indicates Morgan Stanley's positive outlook on BeiGene's stock, reflecting the firm's confidence in the company's current product line and its pipeline's potential to drive future growth. The new price target of $300.00 represents a significant increase from previous assessments and signals expectations for the company's strong performance.
In other recent news, BeiGene has experienced a series of significant developments. The biopharmaceutical company reported third-quarter earnings that exceeded consensus estimates, with a revenue of $1.1 billion, a 28% increase from the same period last year.
The improvement was driven by robust sales of their cancer drug, BRUKINSA, in the US and Europe. However, the company reported a narrower loss per share of $0.09, lower than the prior-year quarter's earnings per share of $0.15.
Furthermore, BeiGene has resolved ongoing patent litigation with MSN Pharmaceuticals concerning BRUKINSA, ensuring market exclusivity for this key product in its oncology portfolio well into the next decade. This resolution is critical for BeiGene's revenue and was followed by a price target upgrade from $254 to $260 by analyst firm TD Cowen, which maintained a Buy rating for the company.
In other company news, BeiGene announced a proposed name change to BeOne Medicines Ltd., pending shareholder approval, to better align with its corporate identity. This rebranding will also involve a new ticker symbol, "ONC", on the NASDAQ Global Select Market. These are just a few of the recent developments for BeiGene.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.